tipifarnib has been researched along with palbociclib in 6 studies
Studies (tipifarnib) | Trials (tipifarnib) | Recent Studies (post-2010) (tipifarnib) | Studies (palbociclib) | Trials (palbociclib) | Recent Studies (post-2010) (palbociclib) |
---|---|---|---|---|---|
309 | 92 | 94 | 911 | 126 | 864 |
Protein | Taxonomy | tipifarnib (IC50) | palbociclib (IC50) |
---|---|---|---|
Chain B, Cell division protein kinase 6 | Homo sapiens (human) | 0.015 | |
Chain B, Cell division protein kinase 6 | Homo sapiens (human) | 0.015 | |
Cyclin-T1 | Homo sapiens (human) | 1.5085 | |
Cyclin-K | Homo sapiens (human) | 1.207 | |
Cyclin-dependent kinase 1 | Homo sapiens (human) | 9.8 | |
Cyclin-dependent kinase 4 | Homo sapiens (human) | 0.0109 | |
G2/mitotic-specific cyclin-B1 | Homo sapiens (human) | 9.8 | |
Cyclin-A2 | Homo sapiens (human) | 2.2042 | |
Acetylcholinesterase | Mus musculus (house mouse) | 0.021 | |
G1/S-specific cyclin-D1 | Homo sapiens (human) | 0.0115 | |
G1/S-specific cyclin-E1 | Homo sapiens (human) | 9.15 | |
Cyclin-dependent kinase 2 | Homo sapiens (human) | 4.1887 | |
G1/S-specific cyclin-D2 | Homo sapiens (human) | 0.0127 | |
G1/S-specific cyclin-D3 | Homo sapiens (human) | 0.0194 | |
Receptor-type tyrosine-protein kinase FLT3 | Homo sapiens (human) | 3.48 | |
Cyclin-dependent kinase 9 | Homo sapiens (human) | 1.1821 | |
Tyrosine-protein kinase JAK3 | Homo sapiens (human) | 0.0631 | |
Cyclin-dependent kinase 6 | Homo sapiens (human) | 0.018 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 5 (83.33) | 24.3611 |
2020's | 1 (16.67) | 2.80 |
Authors | Studies |
---|---|
Bonovolias, ID; Chatzopoulou, M; Demopoulos, VJ; Nicolaou, I; Tsiftsoglou, AS; Vizirianakis, IS | 1 |
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR | 1 |
Kabir, M; Kerns, E; Nguyen, K; Shah, P; Sun, H; Wang, Y; Xu, X; Yu, KR | 1 |
Kabir, M; Kerns, E; Neyra, J; Nguyen, K; Nguyễn, ÐT; Shah, P; Siramshetty, VB; Southall, N; Williams, J; Xu, X; Yu, KR | 1 |
Cavaco, BM; Leite, V; Lopes-Ventura, S; Marques, IJ; Matias, AT; Moura, MM; Pojo, M | 1 |
1 review(s) available for tipifarnib and palbociclib
Article | Year |
---|---|
Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Differentiation; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Leukemia; Multipotent Stem Cells; Neoplastic Stem Cells; Pharmacogenetics | 2010 |
5 other study(ies) available for tipifarnib and palbociclib
Article | Year |
---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Highly predictive and interpretable models for PAMPA permeability.
Topics: Artificial Intelligence; Caco-2 Cells; Cell Membrane Permeability; Humans; Models, Biological; Organic Chemicals; Regression Analysis; Support Vector Machine | 2017 |
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
Topics: Drug Discovery; Organic Chemicals; Pharmaceutical Preparations; Solubility | 2019 |
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
Topics: Animals; Computer Simulation; Databases, Factual; Drug Discovery; High-Throughput Screening Assays; Liver; Machine Learning; Male; Microsomes, Liver; National Center for Advancing Translational Sciences (U.S.); Pharmaceutical Preparations; Quantitative Structure-Activity Relationship; Rats; Rats, Sprague-Dawley; Retrospective Studies; United States | 2020 |
The efficacy of HRAS and CDK4/6 inhibitors in anaplastic thyroid cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Proliferation; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Gene Expression Regulation, Neoplastic; Humans; Mutation; Piperazines; Proto-Oncogene Proteins p21(ras); Pyridines; Quinolones; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Tumor Cells, Cultured | 2019 |